The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.
 
Emmanuel Bachy
Honoraria - Amgen; Gilead Sciences; Janssen-Cilag; Novartis; Roche; Takeda
Consulting or Advisory Role - Gilead Sciences; Incyte; Roche; Takeda
Research Funding - Amgen Foundation (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Incyte; Janssen-Cilag; Roche
 
Kerry J. Savage
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Kyowa; Merck; Novartis; Novartis; Novartis Canada Pharmaceuticals Inc; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Merck; Seagen; Servier
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Seagen
(OPTIONAL) Uncompensated Relationships - Beigene
 
Huiqiang Huang
No Relationships to Disclose
 
Yok-Lam Kwong
No Relationships to Disclose
 
Giuseppe Gritti
Consulting or Advisory Role - Clinigen Group; Gilead Sciences; IQvia; Italfarmaco; Roche; Takeda
Speakers' Bureau - Amgen; Roche
Travel, Accommodations, Expenses - Gilead Sciences; Janssen
 
Qingyuan Zhang
No Relationships to Disclose
 
Anna Marina Liberati
Consulting or Advisory Role - SERVIER
Research Funding - Abbvie (Inst); Amgen (Inst); Archigen Biotech (Inst); beigene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); FibroGen (Inst); Incyte (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Oncopeptides (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst); verastem (Inst)
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Celgene; IQvia; Novartis; Novartis; Roche; Sanofi; Takeda; Verastem
 
Junning Cao
No Relationships to Disclose
 
Haiyan Yang
No Relationships to Disclose
 
Siguo Hao
No Relationships to Disclose
 
Jianda Hu
No Relationships to Disclose
 
Keshu Zhou
No Relationships to Disclose
 
Filomena Russo
No Relationships to Disclose
 
Huilai Zhang
No Relationships to Disclose
 
Wei Sang
No Relationships to Disclose
 
Jie Ji
No Relationships to Disclose
 
Hui Liu
No Relationships to Disclose
 
Sha Huang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis